Novel Therapeutic Targets in Axial Spondyloarthritis

Overview

Journal Curr Treatm Opt Rheumatol

Date 2018 Jun 26

PMID 29938195

Citations 6

Authors

Claudia Worth

Paul Bowness

M Hussein Al-Mossawi

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Axial spondyloarthritis remains an area of significant unmet clinical need with only two immune pathways currently targeted by licenced therapies compared to other immune-mediated inflammatory joint disorders such as rheumatoid arthritis where a multitude of therapeutic options are available. This review will look at emerging therapeutic targets in axial spondyloarthritis beyond the neutralisation of IL-17A and TNF by monoclonal antibodies.

Recent Findings: Several promising targets are in various stages of pre-clinical and clinical development in axial spondyloarthritis. These include small molecule approaches to target transcription factors, epigenetic modification and intracellular modulation of cytokine signalling by kinase inhibition. GM-CSF has also emerged as a potential driver of inflammation.

Summary: A number of novel and promising therapeutic options are in various stages of development in axial spondyloarthritis. The Janus kinase inhibitors have shown great promise in other immune-mediated inflammatory disorders and will be an exciting addition to the axial spondyloarthritis field as the first oral disease-modifying agents. GM-CSF blockade also shows great promise since antibodies for neutralising this cytokine are safe in patients and have shown efficacy in other immune-mediated inflammatory diseases.

Citing Articles

Uncovering the Underworld of Axial Spondyloarthritis.

Vescovo S, Venerito V, Iannone C, Lopalco G Int J Mol Sci. 2023; 24(7).

PMID: 37047435 PMC: 10095023. DOI: 10.3390/ijms24076463.

Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents.

Tahir H, Byravan S, Fardanesh A, Moorthy A J Exp Pharmacol. 2021; 13:627-635.

PMID: 34257507 PMC: 8269276. DOI: 10.2147/JEP.S262340.

A novel IMU-based clinical assessment protocol for Axial Spondyloarthritis: a protocol validation study.

Franco L, Sengupta R, Wade L, Cazzola D PeerJ. 2021; 9:e10623.

PMID: 33569248 PMC: 7845531. DOI: 10.7717/peerj.10623.

Treatment strategies in axial spondyloarthritis: what, when and how?.

Fragoulis G, Siebert S Rheumatology (Oxford). 2020; 59(Suppl4):iv79-iv89.

PMID: 33053192 PMC: 7566463. DOI: 10.1093/rheumatology/keaa435.

Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Alfaleh M, Alsaab H, Mahmoud A, Alkayyal A, Jones M, Mahler S Front Immunol. 2020; 11:1986.

PMID: 32983137 PMC: 7485114. DOI: 10.3389/fimmu.2020.01986.

References

Kotake S, Higaki M, Sato K, Himeno S, Morita H, Kim K . Detection of myeloid precursors (granulocyte/macrophage colony forming units) in the bone marrow adjacent to rheumatoid arthritis joints. J Rheumatol. 1992; 19(10):1511-6. View

Hammitzsch A, Tallant C, Fedorov O, OMahony A, Brennan P, Hay D . CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A. 2015; 112(34):10768-73. PMC: 4553799. DOI: 10.1073/pnas.1501956112. View

Walker L, Kang Y, Smith M, Tharmalingham H, Ramamurthy N, Fleming V . Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells. Blood. 2011; 119(2):422-33. PMC: 3257008. DOI: 10.1182/blood-2011-05-353789. View

Hamilton J . GM-CSF in inflammation and autoimmunity. Trends Immunol. 2002; 23(8):403-8. DOI: 10.1016/s1471-4906(02)02260-3. View

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P . Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015; 373(26):2534-48. DOI: 10.1056/NEJMoa1505066. View

Menon B, Gullick N, Walter G, Rajasekhar M, Garrood T, Evans H . Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014; 66(5):1272-81. PMC: 4158887. DOI: 10.1002/art.38376. View

Delvecchio M, Gaucher J, Aguilar-Gurrieri C, Ortega E, Panne D . Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation. Nat Struct Mol Biol. 2013; 20(9):1040-6. DOI: 10.1038/nsmb.2642. View

Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E . 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011; 70(6):896-904. PMC: 3086052. DOI: 10.1136/ard.2011.151027. View

Burmester G, Feist E, Sleeman M, Wang B, White B, Magrini F . Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis. 2011; 70(9):1542-9. PMC: 3147227. DOI: 10.1136/ard.2010.146225. View

10.

Boniface K, Bak-Jensen K, Li Y, Blumenschein W, McGeachy M, McClanahan T . Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009; 206(3):535-48. PMC: 2699124. DOI: 10.1084/jem.20082293. View

11.

Al-Mossawi M, Chen L, Fang H, Ridley A, de Wit J, Yager N . Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nat Commun. 2017; 8(1):1510. PMC: 5688161. DOI: 10.1038/s41467-017-01771-2. View

12.

Danis V, Franic G, Rathjen D, Brooks P . Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-2, interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha) and IL-6 on the production of immunoreactive IL-1 and TNF-alpha by human monocytes. Clin Exp Immunol. 1991; 85(1):143-50. PMC: 1535710. DOI: 10.1111/j.1365-2249.1991.tb05695.x. View

13.

Taylor P, Keystone E, van der Heijde D, Weinblatt M, Del Carmen Morales L, Reyes Gonzaga J . Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017; 376(7):652-662. DOI: 10.1056/NEJMoa1608345. View

14.

Burmester G, McInnes I, Kremer J, Miranda P, Korkosz M, Vencovsky J . A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2017; 76(6):1020-1030. DOI: 10.1136/annrheumdis-2016-210624. View

15.

Cook A, Louis C, Robinson M, Saleh R, Sleeman M, Hamilton J . Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation. Arthritis Res Ther. 2016; 18(1):287. PMC: 5134062. DOI: 10.1186/s13075-016-1185-9. View

16.

Reveille J . Epidemiology of spondyloarthritis in North America. Am J Med Sci. 2011; 341(4):284-6. PMC: 3063892. DOI: 10.1097/MAJ.0b013e31820f8c99. View

17.

van Vollenhoven R, Fleischmann R, Cohen S, Lee E, Garcia Meijide J, Wagner S . Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367(6):508-19. DOI: 10.1056/NEJMoa1112072. View

18.

Schweizerhof M, Stosser S, Kurejova M, Njoo C, Gangadharan V, Agarwal N . Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med. 2009; 15(7):802-7. DOI: 10.1038/nm.1976. View

19.

Cua D, Tato C . Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010; 10(7):479-89. DOI: 10.1038/nri2800. View

20.

Greven D, Cohen E, Gerlag D, Campbell J, Woods J, Davis N . Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis. Ann Rheum Dis. 2014; 74(10):1924-30. PMC: 4602263. DOI: 10.1136/annrheumdis-2014-205234. View